Cerebral venous sinus thrombosis secondary prevention: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
== Overview == | == Overview == | ||
For patients with [[cerebral venous thrombosis]], a long-term [[anticoagulant]] is highly recommended to prevent future events. | |||
==Secondary prevention== | ==Secondary prevention== | ||
Latest revision as of 17:07, 1 August 2021
|
Cerebral venous sinus thrombosis Microchapters |
|
Differentiating Cerebral venous sinus thrombosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cerebral venous sinus thrombosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Cerebral venous sinus thrombosis secondary prevention |
|
FDA on Cerebral venous sinus thrombosis secondary prevention |
|
CDC on Cerebral venous sinus thrombosis secondary prevention |
|
Cerebral venous sinus thrombosis secondary prevention in the news |
|
Blogs on Cerebral venous sinus thrombosis secondary prevention |
|
Directions to Hospitals Treating Cerebral venous sinus thrombosis |
|
Risk calculators and risk factors for Cerebral venous sinus thrombosis secondary prevention |
Associate editor in chief: Sharmi Biswas, M.B.B.S
Overview
For patients with cerebral venous thrombosis, a long-term anticoagulant is highly recommended to prevent future events.
Secondary prevention
Long term anticoagulant should be considered in patients with history of pulmonary thrombosis or deep venous thrombosis.[1]
References
- ↑ van Nuenen, B.F.L.; Munneke, M.; Bloem, B.R. (2005). "Cerebral Venous Sinus Thrombosis: Prevention of Recurrent Thromboembolism". Stroke. 36 (9): 1822–1823. doi:10.1161/01.STR.0000176582.17934.82. ISSN 0039-2499.